Emergent BioSolutions (EBS) Cash Flow Statement

Click line-items for a historical chart and %

Net income (loss)	14.38M
Stock-based compensation expense	14.53M
Depreciation and amortization	28.16M
Deferred income taxes	4.81M
Non-cash development expenses from variable interest entities
Impairment of long-lived assets	3.75M
Change in fair value of contingent value rights
Excess tax benefits from stock-based compensation	-10.83M
Other	2.47M
Accounts receivable	45.04M
Inventories	-16.18M
Income taxes	-14.66M
Prepaid expenses and other assets	-3.15M
Accounts payable	-1.31M
Accrued expenses and other liabilities	-1.7M
Accrued compensation	-152K
Deferred revenue	-1.35M
Net cash (used in) provided by operating activities
Purchases of property, plant and equipment	-56.24M
Purchase of investments
Proceeds from maturity of investments
Net cash used in investing activities
Proceeds from borrowing on line of credit
Issuance of common stock subject to exercise of stock options	14.98M
Principal payments on long-term indebtedness and line of credit
Excess tax benefits from stock-based compensation	10.83M
Net cash provided by (used in) financing activities
Effect of exchange rate changes on cash and cash equivalents	139K
Net increase (decrease) in cash and cash equivalents	-13.86M
Cash and cash equivalents at beginning of period	312.8M
Cash and cash equivalents at end of period	298.93M

Entities mentioned with EBS

View All Entities